STJ  St. Jude Medical Inc.

Exchange

NYSE

Sector

Health Care

Industry

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Market Cap.

21.64B

Vuru Grade

63.43/100

Current Price

$76.30
-1.49 (-1.92%)

Growth Price

$42.96
Overvalued by 43.69%

Stability Price

$7.57
Overvalued by 90.07%

Company Metrics

  • P/E 24.85
  • P/S 3.98
  • P/B 5.46
  • EPS 3.07
  • Cash ROIC 13.51%
  • Cash Ratio 0.27
  • Dividend 1.24 / 2.06 %
  • Avg. Vol. 2.63M
  • Shares 283.62M
  • Market Cap. 21.64B

Company Description

St. Jude Medical, Inc. develops, manufactures, and distributes cardiovascular and implantable neurostimulation medical devices worldwide. It operates in four segments: Cardiac Rhythm Management, Cardiovascular, Atrial Fibrillation, and Neuromodulation. The Cardiac Rhythm Management segment offers products for cardiac arrhythmias, or irregular heart beats. Its products include tachycardia implantab... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Ryan & Maniskas, LLP Announces Investigation of St. Jude Medical Inc.
PR Newswire (press release) - 5 hours ago
WAYNE, Pa., April 29, 2016 /PRNewswire/ -- Ryan & Maniskas, LLP is investigating potential claims against the board of directors of St. Jude Medical Inc. ("St. Jude Medical" or the "Company") (NYSE: STJ) concerning possible breaches of fiduciary duty ...
Correction: Abbott-St Jude Acquisition story - WSB Atlanta
Why Dreamworks Animation Skg Inc (DWA), St. Jude Medical, Inc. (STJ) and ...
Investorplace.com - 23 hours ago
Why Dreamworks Animation Skg Inc (DWA), St. Jude Medical, Inc. With the yen being one of this year's preferred safe-haven destinations, stocks could not endure the storm even though oil climbed to its highest levels since early November.
ST. JUDE MEDICAL, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces ... - Business Wire (press release)
Moody's reviews St. Jude Medical's Baa2 rating for downgrade
Moodys.com (press release) (subscription) - 22 hours ago
New York, April 28, 2016 -- Moody's Investors Service placed the ratings of St. Jude Medical, Inc.(Baa2/Prime-2) under review for downgrade.
Summary of Analyst's Study: St. Jude Medical, Inc. (NYSE:STJ) , Vertex ...
Street Updates - 8 hours ago
St. Jude Medical, Inc. (NYSE:STJ) increased +25.57% or +15.84 points. The company traded volume of 32.96 million shares more than average volume of 2.15 million shares.
Abbott Labs to spend $19.3 billion to buy St. Jude Medical
STLtoday.com - Apr 28, 2016
This July 29, 2015 photo shows a sign at the Abbott Laboratories campus in Abbott Park, Ill. Abbott Laboratories will buy St. Jude Medical Inc. in a cash-stock deal that aims to strengthen the medical device maker's share of the market for ...
3 Stocks to Watch on Thursday: Marriott International Inc (MAR), St. Jude ...
Investorplace.com - Apr 28, 2016
Another string of companies reported fiscal results for their most recent periods, including the likes of Marriott International Inc (NASDAQ:MAR) and Texas Instruments Incorporated (NASDAQ:TXN).
Analysts Keeping an Eye on St. Jude Medical Inc. (STJ)
CWRU Observer - Apr 28, 2016
St. Jude Medical Inc. (STJ) shares traded up 2.94% during last trading, hitting $61.95. The shares of STJ currently has mean rating of Outperform while 6 analysts have recommended the shares as BUY, 7 recommended as OUTPERFORM and 12 ...
St. Jude Medical Inc. (STJ) Pops 2.94% for April 27
Equities.com - Apr 27, 2016
One of the S&P 500's big winners for Wednesday April 27 was St. Jude Medical Inc. (STJ) as the company's stock climbed 2.94% to $61.95 on volume of 2.97 million shares.
St. Jude Medical Inc. (STJ) Pops 25.57% for April 28
Equities.com - 22 hours ago
One of the S&P 500's big winners for Thursday April 28 was St. Jude Medical Inc. (STJ) as the company's stock climbed 25.57% to $77.79 on volume of 32.95 million shares.
Abbott to spend $19.3B to buy St. Jude Medical - WQOW TV: Eau Claire, WI ...
WQOW TV News 18 - Apr 28, 2016
Abbott Laboratories will spend $19.3 billion to buy St. Jude Medical Inc. in a cash-stock deal that aims to strengthen the medical device maker's share of the market for cardiovascular care.